|Synonyms||NC30 (Human), P600 (Murine);IL-13 (human)|
|Description||Interleukin 13 (IL-13) is an immunoregulatory cytokine produced primarily by activated Th2 cells, and also by mast cells and NK cells. Targeted deletion of IL-13 in mice resulted in impaired Th2 cell development and indicated an important role for IL-13 in the expulsion of gastrointestinal parasites. IL-13 exerts anti-inflammatory effects on monocytes and macrophages and it inhibits the expression of inflammatory cytokines such as IL-1beta, TNF-alpha, IL-6 and IL-8. IL-13 has also been shown to enhance B cell proliferation and to induce isotype switching resulting in increased production of IgE. Blocking of IL-13 activity inhibits the pathophysiology of asthma. Human and mouse IL-13 is cross-species reactive.
Recombinant human interleukin 13 expressed in CHO cells is glycosylated protein with molecular weight range from 25 to 45 kDa shown in non-reducing SDS-PAGE.
|Biological Activity||ED50 < 15 ng/ml, measured in a cell proliferation assay using TF-1 cells, corresponding to a specific activity of > 6.7×105 units/mg.|
SPGPVPPSTA LRELIEELVN ITQNQKAPLC NGSMVWSINL
TAGMYCAALE SLINVSGCSA IEKTQRMLSG FCPHKVSAGQ
FSSLHVRDTK IEVAQFVKDL LLHLKKLFRE GRFN
|Measured Molecular Weight||25-45 kDa, observed by non-reducing SDS-PAGE.|
|Purity||> 95% as analyzed by SDS-PAGE.|
|Formulation||Lyophilized after extensive dialysis against PBS.|
|Reconstitution||Reconstituted in ddH2O or PBS at 100 μg/ml.|
|Endotoxin Level||< 0.2 EU/μg, determined by LAL method.|
|Storage||Lyophilized recombinant human Interleukin 13 (IL-13) remains stable up to 6 months at lower than -70°C from date of receipt. Upon reconstitution, rhIL-13 should be stable up to 1 week at 4°C or up to 2 months at -20°C.|
|Note||For research use only|